![Kim Seth](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kim Seth
Corporate Officer/Principal en REPARE THERAPEUTICS INC. .
Fortuna: 88 329 $ al 31/05/2024
Perfil
Kim Seth was the founder of Resilience Therapeutics, Inc. founded in 2015, where he held the title of Director, Chief Operating & Business Officer from 2015 to 2017.
He is currently the EVP, Head-Business & Corporate Development at Repare Therapeutics, Inc. since 2017.
Prior to this, he worked as the Executive Director-Worldwide R&D at Pfizer Inc. from 2011 to 2014 and as Vice President at Goldman Sachs & Co. LLC from 2006 to 2010.
He was also the Chief Business Officer at Zalicus, Inc. and the Chief Business Officer & Senior Vice President at EPIRUS Biopharmaceuticals, Inc. from 2014 to 2015.
Dr. Seth holds a doctorate degree from Harvard University and an undergraduate degree from Harvard College.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
REPARE THERAPEUTICS INC.
0.06% | 01/04/2024 | 25 382 ( 0.06% ) | 88 329 $ | 31/05/2024 |
Cargos activos de Kim Seth
Empresas | Cargo | Inicio |
---|---|---|
REPARE THERAPEUTICS INC. | Corporate Officer/Principal | 01/06/2017 |
Antiguos cargos conocidos de Kim Seth.
Empresas | Cargo | Fin |
---|---|---|
Resilience Therapeutics, Inc.
![]() Resilience Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Resilience Therapeutics, Inc. operates as a pharmaceuticals store. The company was founded by Retsina Meyer, Brad Geddes and Veronica Weiner and is headquartered in Duxbury, MA. | Fundador | 01/05/2017 |
EPIRUS BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2015 |
PFIZER, INC. | Corporate Officer/Principal | 01/02/2014 |
Goldman Sachs & Co. LLC
![]() Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Corporate Officer/Principal | 01/06/2010 |
Zalicus, Inc.
![]() Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Formación de Kim Seth.
Harvard University | Doctorate Degree |
Harvard College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
PFIZER, INC. | Health Technology |
EPIRUS BIOPHARMACEUTICALS, INC. | Health Technology |
REPARE THERAPEUTICS INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Resilience Therapeutics, Inc.
![]() Resilience Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Resilience Therapeutics, Inc. operates as a pharmaceuticals store. The company was founded by Retsina Meyer, Brad Geddes and Veronica Weiner and is headquartered in Duxbury, MA. | Health Technology |
Goldman Sachs & Co. LLC
![]() Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Finance |
Zalicus, Inc.
![]() Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Kim Seth